ArticleClinical cancer research : an official journal of the American Association for Cancer Research2017
Multifaceted Role of BTLA in the Control of CD8
Open access · bronzeAbstract read
In one paragraph
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 49 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
49citing papers in PubMed, 1 pooled it
2.5field-weighted citation impact, top 9% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
49 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.
- Prognostic Value of Tumor-Infiltrating Lymphocytes Differs Depending on Lymphocyte Subsets in Esophageal Squamous Cell Carcinoma: An Updated Meta-Analysis.Frontiers in oncology · 2020Pooled it
- T cell receptor repertoire dynamics and newly identified functional regulators of autologous tumor-infiltrating lymphocyte therapy in advanced solid tumors.Journal of translational medicine · 2026Article
- Triple-Negative Breast Cancer: Molecular Subtypes; Immune Escape; Limitations of Current Immunotherapy; and the BTLA/HVEM/CD160 Axis as an Emerging Target.Current issues in molecular biology · 2026Review
- A comprehensive review of mechanisms underlying resistance to immune checkpoint inhibitors.Frontiers in immunology · 2026Review
- BTLA: An Emerging Immune Checkpoint Target in Cancer Immunotherapy.Pharmaceuticals (Basel, Switzerland) · 2025Review
- IL-2-independent expansion, persistence, and antitumor activity in TIL expressing regulatable membrane-bound IL-15.Molecular therapy : the journal of the American Society of Gene Therapy · 2025Article
- Pan-Cancer Landscape of B- and T-Lymphocyte Attenuator: Implications for Potential Immunotherapy Combinations.JCO precision oncology · 2025Article
- Advances in molecular pathology and therapy of non-small cell lung cancer.Signal transduction and targeted therapy · 2025Review
- CD28 Superfamily Costimulatory Molecules in Chronic Pain: Focus on Immunomodulation.Molecular neurobiology · 2025Review
- Integrated Analysis of Single-Cell and Bulk RNA Data Reveals Complexity and Significance of the Melanoma Interactome.Cancers · 2025Article
- Mechanisms and clinical advancements of cell-based immunotherapies in non-small cell lung cancer: an integrated perspective.Frontiers in immunology · 2025Review
- SLAMF7 (CD319) enhances cytotoxic T-cell differentiation and sensitizes CD8Frontiers in immunology · 2025Article
- The role of immunotherapy and chemotherapy combinations in TKI-resistant EGFR-mutant non-small cell lung cancer: insights from real-world evidence.American journal of cancer research · 2025Article
- High dimensional proteomic mapping of bone marrow immune characteristics in immune thrombocytopenia.Science China. Life sciences · 2024Article
- Article
- The BTLA-HVEM axis restricts CAR T cell efficacy in cancer.Nature immunology · 2024Article
- Distinct characteristics of BTLA/HVEM axis expression on Tregs and its impact on the expansion and attributes of Tregs in patients with active pulmonary tuberculosis.Frontiers in cellular and infection microbiology · 2024Article
- Beyond the anti-PD-1/PD-L1 era: promising role of the BTLA/HVEM axis as a future target for cancer immunotherapy.Molecular cancer · 2023Review
- Chlorogenic Acid Induced Neuroblastoma Cells Differentiation via the ACAT1-TPK1-PDH Pathway.Pharmaceuticals (Basel, Switzerland) · 2023Article
- SOX9 drives KRAS-induced lung adenocarcinoma progression and suppresses anti-tumor immunity.Oncogene · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 3 institutions in 1 country.
Krit RitthipichaiDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Cara L HaymakerDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Melisa MartinezDepartment of Chemical and Biomolecular Engineering, Cullen College of Engineering, University of Houston, Texas.
Andrew AschenbrennerGraduate Program in Biostatistics, School of Public Health, The University of Texas Health Science Center at Houston, Houston, Texas.
Xiaohui YiImmunology Platform, Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Minying ZhangDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Charuta KaleDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Luis M VenceImmunology Platform, Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Jason RoszikDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Yared HailemichaelDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Willem W OverwijkDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Navin VaradarajanDepartment of Chemical and Biomolecular Engineering, Cullen College of Engineering, University of Houston, Texas.
Roza NurievaGraduate Program in Immunology, Graduate School of Biomedical Sciences, The University of Texas Health Science Center at Houston, Houston, Texas.
Laszlo G RadvanyiDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Patrick HwuDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.
Chantale BernatchezDepartment of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas. cbernatchez@mdanderson.org.
The University of Texas MD Anderson Cancer Center · USUniversity of Houston · USThe University of Texas Health Science Center at Houston · US
Funding
Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Fabien Delerue · 1985 to 2026
$290.8MQuantitative single-cell biomarkers of T-cells to optimize tumor immunotherapyR01CA174385 · NCI · UNIVERSITY OF HOUSTON · PI COOPER, LAURENCE J.N., VARADARAJAN, NAVIN · 2012 to 2015
$2.1MDC Vaccination to Enhance Adoptive T Cell TransferR01CA111999 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI HWU, PATRICK · 2006 to 2010
$1.8MSTAT1: New regulator of inflammatory Th17 and Th2 cellsR21AI120012 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI NURIEVA, ROZA INSAFETDINOVNA · 2016 to 2017
$440kFunctional Attributes of a CD8+BTLA+ T cell subset in Adoptive T Cell TherapyR21CA178580 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BERNATCHEZ, CHANTALE · 2013 to 2014
$377kRole of Grail in maintaining humoral immune toleranceR03AI120027 · NIAID · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI NURIEVA, ROZA INSAFETDINOVNA · 2015 to 2016
$160kNCI NIH HHS P30 CA016672NCI NIH HHS R01 CA111999NCI NIH HHS R01 CA174385NCI NIH HHS R21 CA178580NIAID NIH HHS R03 AI120027NIAID NIH HHS R21 AI120012
Abstract
PubMed holds no abstract for this paper.
Indexed as
AnimalsAntigens, NeoplasmCD8-Positive T-LymphocytesCell Line, TumorCytokinesCytotoxicity, ImmunologicGene ExpressionHeterograftsHumansImmunologic MemoryLymphocyte ActivationLymphocytes, Tumor-InfiltratingMelanomaMelanoma, ExperimentalMiceMice, KnockoutAntigens, NeoplasmBTLA protein, humanCytokinesNF-kappa BReceptors, Immunologicsrc-Family Kinases
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.